~~<i id='FB061361D2'><strike id='FB061361D2'><tt id='FB061361D2'><pre id='FB061361D2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：focus 2025-09-05 11:24:10 - browse：289

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： What happened to the House vote on health price transparency?

Wikipedia

leisure time

explore

leisure time

explore

Atissuesamplewiththepresenceofnumerous,corkscrew-shaped,darklystainedTreponemapallidumspirochetes,th

WSS

Information blocking fines are now fair game in health care

Senate bill would ban some hospital facility fees

David Liu startup to focus on CRISPR delivery

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Philips to halt sales of sleep apnea machines in U.S.

leisure time

entertainment

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

Covid’s new normal has set in amid another rise in cases

At least 13 dead in Texas as scorching temps continue

Transgender sports debate: Physicians say bans are health issue

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare Advantage insurers face 0.2% cut to 2025 payments

Peter Hotez and the public health issue of online harassment

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

The cancer drug shortage isn’t new — and neither are the solutions

Medicare Advantage insurers face 0.2% cut to 2025 payments

leisure time

FDA panel to weigh safety of artificial wombs for preterm births

10 reasons why health care startups fail

Why Medicare shouldn’t cover every FDA

What happened to the House vote on health price transparency?

Chamber of Commerce, DOJ clash in court over drug prices

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

explore

explore

leisure time

explore